Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Hypercholesterolemia

  • Home
  • Hypercholesterolemia
Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for Hypercholesterolemia: Results From a Phase 1 Trial
Posted inCardiology news

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for Hypercholesterolemia: Results From a Phase 1 Trial

Posted by MedXY By MedXY 05/15/2026
Laroprovstat, an investigational oral PCSK9 inhibitor, was well tolerated and produced substantial LDL cholesterol reductions, especially when combined with rosuvastatin, supporting further development for hypercholesterolemia.
Read More
Screening Children and Young Adults for Familial Hypercholesterolemia: Clinically Helpful but Not Cost‑Effective
Posted inCardiology news Pediatrics Public Health

Screening Children and Young Adults for Familial Hypercholesterolemia: Clinically Helpful but Not Cost‑Effective

Posted by MedXY By MedXY 11/10/2025
A modeling study found that sequential population screening for familial hypercholesterolemia (FH) at ages 10 or 18 is clinically effective but not cost‑effective versus usual care, unless follow-up monitoring and lifestyle interventions for non‑FH dyslipidemia increase substantially.
Read More
  • Pre-Transplant Left Atrial Volume Index as a Predictor of One-Year Morbidity after Kidney Transplantation: Insights and Implications
  • Normothermic Regional Perfusion: A Paradigm Shift in Pancreas and Islet Transplantation from DCD Donors
  • A Practical Framework for Pyoderma Gangrenosum: Expert Consensus Defines Phenotypes and Modifiers
  • Early Prediction of Dupilumab Efficacy in Facial Atopic Dermatitis via Reflectance Confocal Microscopy and Deep Learning
  • Optimizing Breast Augmentation Through Tissue Preservation and 3D Geometric Analysis: Clinical Insights and Outcomes
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in